Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences von O'Toole, Áine, Pybus, Oliver G, Abram, Michael E, Kelly, Elizabeth J, Rambaut, Andrew

Volltext

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial von Madhavan, Meera, Ritchie, Adam J., Aboagye, Jeremy, Jenkin, Daniel, Provstgaad-Morys, Samuel, Tarbet, Iona, Woods, Danielle, Davies, Sophie, Baker, Megan, Platt, Abigail, Flaxman, Amy, Smith, Holly, Belij-Rammerstorfer, Sandra, Wilkins, Deidre, Kelly, Elizabeth J., Villafana, Tonya, Green, Justin A., Poulton, Ian, Lambe, Teresa, Hill, Adrian V.S., Ewer, Katie J., Douglas, Alexander D.

Volltext

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials von Ahani, Bahar, Tuffy, Kevin M., Aksyuk, Anastasia A., Wilkins, Deidre, Abram, Michael E., Dagan, Ron, Domachowske, Joseph B., Guest, Johnathan D., Ji, Hong, Kushnir, Anna, Leach, Amanda, Madhi, Shabir A., Mankad, Vaishali S., Simões, Eric A. F., Sparklin, Benjamin, Speer, Scott D., Stanley, Ann Marie, Tabor, David E., Hamrén, Ulrika Wählby, Kelly, Elizabeth J., Villafana, Tonya

Volltext

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months von Sobieszczyk, Magdalena E, Maaske, Jill, Falsey, Ann R, Sproule, Stephanie, Robb, Merlin L, Frenck, Jr, Robert W, Tieu, Hong-Van, Mayer, Kenneth H, Corey, Lawrence, Neuzil, Kathleen M, Tong, Tina, Brewinski Isaacs, Margaret, Janes, Holly, Bansal, Himanshu, Edwards, Lindsay M, Green, Justin A, Kelly, Elizabeth J, Shoemaker, Kathryn, Takas, Therese, White, Tom, Bhuyan, Prakash, Villafana, Tonya, Hirsch, And Ian

Volltext

Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial von Asano, Michiko, Okada, Hiroshi, Itoh, Yohji, Hirata, Hajime, Ishikawa, Kensuke, Yoshida, Erika, Matsui, Akiko, Kelly, Elizabeth J., Shoemaker, Kathryn, Olsson, Urban, Vekemans, Johan

Volltext

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection von Brady, Tyler, Cayatte, Corinne, Roe, Tiffany L., Speer, Scott D., Ji, Hong, Machiesky, LeeAnn, Zhang, Tianhui, Wilkins, Deidre, Tuffy, Kevin M., Kelly, Elizabeth J.

Volltext

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination von Cohen, Taylor S., Kelly, Elizabeth J., Nylander, Sven, Bansal, Himanshu, Jepson, Brett M., Bhuyan, Prakash, Sobieszczyk, Magdalena E., Falsey, Ann R.

Volltext

MicroRNAs and the Regulation of Vector Tropism von Kelly, Elizabeth J, Russell, Stephen J

Volltext

Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting von KELLY, Elizabeth J, NACE, Rebecca, BARBER, Glen N, RUSSELL, Stephen J

Volltext

Author Correction: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials von Ahani, Bahar, Tuffy, Kevin M., Aksyuk, Anastasia A., Wilkins, Deidre, Abram, Michael E., Dagan, Ron, Domachowske, Joseph B., Guest, Johnathan D., Ji, Hong, Kushnir, Anna, Leach, Amanda, Madhi, Shabir A., Mankad, Vaishali S., Simões, Eric A. F., Sparklin, Benjamin, Speer, Scott D., Stanley, Ann Marie, Tabor, David E., Hamrén, Ulrika Wählby, Kelly, Elizabeth J., Villafana, Tonya

Volltext

MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference von Kelly, Elizabeth J, Hadac, Elizabeth M, Cullen, Bryan R, Russell, Stephen J

Volltext

Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity von Stanley, Ann Marie, Aksyuk, Anastasia A, Wilkins, Deidre, Green, Justin A, Lan, Dongmei, Shoemaker, Kathryn, Tieu, Hong-Van, Sobieszczyk, Magdalena E, Falsey, Ann R, Kelly, Elizabeth J

Volltext

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 von Levin, Myron J., Ustianowski, Andrew, De Wit, Stéphane, Launay, Odile, Avila, Miles, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Ellery, Adam, Levinson, Dennis J., Ambery, Philip, Arends, Rosalinda H., Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J., Koh, Gavin C.K.W., Near, Karen A., Padilla, Kelly W., Psachoulia, Konstantina, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N., Esser, Mark T.

Volltext

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated von Maaske, Jill, Sproule, Stephanie, Falsey, Ann R, Sobieszczyk, Magdalena E, Luetkemeyer, Anne F, Paulsen, Grant C, Riddler, Sharon A, Robb, Merlin L, Rolle, Charlotte-Paige, Sha, Beverly E, Tong, Tina, Ahani, Bahar, Aksyuk, Anastasia A, Bansal, Himanshu, Egan, Timothy, Jepson, Brett, Padilla, Marcelino, Patel, Nirmeshkumar, Shoemaker, Kathryn, Stanley, Ann Marie, Swanson, Phillip A, Wilkins, Deidre, Villafana, Tonya, Green, Justin A, Kelly, Elizabeth J

Volltext

Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination von Wilkins, Deidre, Aksyuk, Anastasia A, Ruzin, Alexey, Tuffy, Kevin M, Green, Tina, Greway, Rebecca, Fikes, Brittany, Bonhomme, Cyrille J, Esser, Mark T, Kelly, Elizabeth J

Volltext

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants von Roe, Tiffany L, Brady, Tyler, Schuko, Nicolette, Nguyen, Amy, Beloor, Jagadish, Guest, Johnathan D, Aksyuk, Anastasia A, Tuffy, Kevin M, Zhang, Tianhui, Streicher, Katie, Kelly, Elizabeth J, Kijak, Gustavo H

Volltext

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine von Falsey, Ann R, Sobieszczyk, Magdalena E, Hirsch, Ian, Sproule, Stephanie, Robb, Merlin L, Corey, Lawrence, Neuzil, Kathleen M, Hahn, William, Hunt, Julie, Mulligan, Mark J, McEvoy, Charlene, DeJesus, Edwin, Hassman, Michael, Little, Susan J, Pahud, Barbara A, Durbin, Anna, Pickrell, Paul, Daar, Eric S, Bush, Larry, Solis, Joel, Carr, Quito Osuna, Oyedele, Temitope, Buchbinder, Susan, Cowden, Jessica, Vargas, Sergio L, Guerreros Benavides, Alfredo, Call, Robert, Keefer, Michael C, Kirkpatrick, Beth D, Pullman, John, Tong, Tina, Brewinski Isaacs, Margaret, Benkeser, David, Janes, Holly E, Nason, Martha C, Green, Justin A, Kelly, Elizabeth J, Maaske, Jill, Mueller, Nancy, Shoemaker, Kathryn, Takas, Therese, Marshall, Richard P, Pangalos, Menelas N, Villafana, Tonya, Gonzalez-Lopez, Antonio

Volltext

Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants von Muller, William J., Madhi, Shabir A., Seoane Nuñez, Beatriz, Baca Cots, Manuel, Bosheva, Miroslava, Dagan, Ron, Hammitt, Laura L., Llapur, Conrado J., Novoa, Jose M., Saez Llorens, Xavier, Grenham, Amy, Kelly, Elizabeth J., Mankad, Vaishali S., Shroff, Manish, Takas, Therese, Leach, Amanda, Villafana, Tonya

Volltext

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12 von Kurokawa, Cheyne, Agrawal, Sonia, Mitra, Abhisek, Galvani, Elena, Burke, Shannon, Varshine, Ankita, Rothstein, Raymond, Schifferli, Kevin, Monks, Noel R, Foloppe, Johann, Silvestre, Nathalie, Quemeneur, Eric, Demeusoit, Christelle, Kleinpeter, Patricia, Sapra, Puja, Barrett, Carl, Hammond, Scott A, Kelly, Elizabeth J, Laliberte, Jason, Durham, Nicholas M, Oberst, Michael, Broggi, Maria A S

Volltext

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial) von Kijak, Gustavo H., Ahani, Bahar, Arbetter, Douglas, Chuecos, Fernando, Gopalakrishnan, Vancheswaran, Beloor, Jagadish, Brady, Tyler, Nguyen, Amy, Roe, Tiffany L., Schuko, Nicolette, Zhang, Tianhui, Hobbs, F. D. Richard, Padilla, Francisco, Kelly, Elizabeth J., Montgomery, Hugh, Streicher, Katie

Volltext